What ICON’s Claude Deal Actually Means for the Site Coordinator Running Your Trial
ICON's Anthropic partnership deploys Claude AI into clinical trials. Here's what it means for EDC workflows, IRB docs, and...
LITMUS Changes the Biopsy Calculus: What the Nature Medicine Data Means for Your MASLD Protocol
A Nature Medicine study using the 10,000-patient LITMUS registry shows non-invasive fibrosis tests can replace liver biopsy endpoints. Here's...
IQVIA Partners With Medera on Cardiac Gene Therapy Development
IQVIA partners with Medera to advance cardiac gene therapy programs for HFpEF, HFrEF, and DMD-associated cardiomyopathy with clinical operations...
Nurix Receives $10M Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader SAR448272
Sanofi initiates Phase 1 trial of STAT6 degrader SAR448272, triggering a $10M payment to Nurix under their ongoing collaboration.
SHY Therapeutics Doses First Patient in SHY-ONC6 Phase 1 Trial for Solid Tumors
SHY Therapeutics doses first patient in SHY-ONC6 Phase 1 trial, testing a novel proteasome inhibitor mechanism for solid tumors...
ORIC Launches Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancer
ORIC Pharmaceuticals launches Himalayas-1, a 600-patient Phase 3 trial of rinzimetostat in metastatic prostate cancer, with results expected later...
RM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial
RM-718 shows 11.6% BMI reduction in acquired hypothalamic obesity trial with reduced hyperpigmentation compared to earlier MC4R agonists.
Tonix Gets FDA Alignment on TNX-4800 Phase 2 Lyme Disease Study Design
Tonix gains FDA alignment on TNX-4800 Phase 2 study design for Lyme disease prevention using a long-acting monoclonal antibody...
Psilocybin Has Crossed the Evidence Threshold. Clinical Guidelines Have Not.
Compass Pathways' Phase 3 six-month data and a first-ever psilocybin-PTSD veteran trial signal readiness — but the guideline infrastructure...
Pediatric Dermatology’s Blind Spot: How Arcutis Built a Drug Pipeline Where the Industry Wouldn’t Look
Frank Watanabe turned a clinician's frustration into a regulatory strategy that has now yielded seven approvals for ZORYVE. The...